GlassScriptPhysician profile
Mila Ju
NPI 1629207352
$35,667.21
in general payments reported to CMS, 2019-2025
12 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Vascular Surgery provider received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $2,609 · 2021: $1,154 · 2022: $19K · 2023: $356 · 2024: $144 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Silk Road Medical, INC. | $33,663.39 | 2019-2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| W. L. Gore & Associates, INC. | $651.32 | 2019-2024 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Gore Tag Thoracic Branch Endoprosthesis |
| Medtronic, INC. | $455.34 | 2021-2025 | Endurant Iis |
| Medtronic USA, INC. | $229.47 | 2019 | |
| Medtronic Vascular, INC. | $190.23 | 2019-2020 | |
| Cook Medical LLC | $189.23 | 2020-2025 | Zenith Spiral-Z |
| Shockwave Medical, INC | $137.25 | 2022 | |
| Boston Scientific Corporation | $52.29 | 2023-2025 | Enroute Transcarotid Neuroprotection System |
| Kci USA, INC. | $37.57 | 2021 | |
| Molnlycke Health Care US, LLC | $22.70 | 2022 | |
| Acera Surgical, INC. | $21.71 | 2025 | Restrata Wound Matrix |
| Janssen Pharmaceuticals, INC | $16.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mila Ju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.